Seamus Fernandez
Stock Analyst at Guggenheim
(2.45)
# 2,180
Out of 4,829 analysts
98
Total ratings
50%
Success rate
19.95%
Average return
Main Sectors:
Stocks Rated by Seamus Fernandez
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Buy | $33 → $35 | $19.43 | +80.13% | 2 | May 9, 2025 | |
| LLY Eli Lilly and Company | Maintains: Buy | $973 → $928 | $755.57 | +22.82% | 15 | Apr 14, 2025 | |
| MBX MBX Biosciences | Reiterates: Buy | $44 | $11.14 | +294.97% | 2 | Apr 10, 2025 | |
| ARQT Arcutis Biotherapeutics | Reiterates: Buy | n/a | $14.39 | - | 3 | Apr 3, 2025 | |
| VERV Verve Therapeutics | Reiterates: Buy | n/a | $4.35 | - | 2 | Mar 25, 2025 | |
| PCVX Vaxcyte | Reiterates: Buy | $160 | $31.59 | +406.49% | 4 | Mar 12, 2025 | |
| MTSR Metsera | Initiates: Buy | $56 | $26.38 | +112.28% | 1 | Feb 25, 2025 | |
| MLYS Mineralys Therapeutics | Reiterates: Buy | n/a | $15.01 | - | 2 | Feb 24, 2025 | |
| APGE Apogee Therapeutics | Reiterates: Buy | n/a | $39.58 | - | 7 | Feb 10, 2025 | |
| MRK Merck & Co. | Maintains: Buy | $137 → $130 | $80.43 | +61.63% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $37.37 | - | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $58.97 | +18.71% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $5.71 | +180.21% | 1 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.89 | - | 3 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.01 | - | 3 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | n/a | $11.59 | - | 2 | Jul 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $24.62 | +103.09% | 1 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $48.18 | - | 12 | Oct 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $67.74 | - | 2 | May 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $108.95 | - | 6 | Feb 25, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.83 | - | 1 | Feb 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $56 → $54 | $1.25 | +4,220.00% | 1 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $60 → $45 | $20.18 | +122.99% | 3 | Mar 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $36 → $38 | $68.95 | -44.89% | 6 | Feb 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $35 → $38 | $23.09 | +64.57% | 3 | Jan 31, 2018 |
Cidara Therapeutics
May 9, 2025
Maintains: Buy
Price Target: $33 → $35
Current: $19.43
Upside: +80.13%
Eli Lilly and Company
Apr 14, 2025
Maintains: Buy
Price Target: $973 → $928
Current: $755.57
Upside: +22.82%
MBX Biosciences
Apr 10, 2025
Reiterates: Buy
Price Target: $44
Current: $11.14
Upside: +294.97%
Arcutis Biotherapeutics
Apr 3, 2025
Reiterates: Buy
Price Target: n/a
Current: $14.39
Upside: -
Verve Therapeutics
Mar 25, 2025
Reiterates: Buy
Price Target: n/a
Current: $4.35
Upside: -
Vaxcyte
Mar 12, 2025
Reiterates: Buy
Price Target: $160
Current: $31.59
Upside: +406.49%
Metsera
Feb 25, 2025
Initiates: Buy
Price Target: $56
Current: $26.38
Upside: +112.28%
Mineralys Therapeutics
Feb 24, 2025
Reiterates: Buy
Price Target: n/a
Current: $15.01
Upside: -
Apogee Therapeutics
Feb 10, 2025
Reiterates: Buy
Price Target: n/a
Current: $39.58
Upside: -
Merck & Co.
Nov 6, 2024
Maintains: Buy
Price Target: $137 → $130
Current: $80.43
Upside: +61.63%
Oct 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $37.37
Upside: -
Oct 21, 2024
Initiates: Buy
Price Target: $70
Current: $58.97
Upside: +18.71%
Oct 14, 2024
Initiates: Buy
Price Target: $16
Current: $5.71
Upside: +180.21%
Jul 8, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.89
Upside: -
Apr 29, 2024
Downgrades: Neutral
Price Target: n/a
Current: $6.01
Upside: -
Jul 14, 2023
Maintains: Buy
Price Target: n/a
Current: $11.59
Upside: -
Feb 28, 2023
Initiates: Buy
Price Target: $50
Current: $24.62
Upside: +103.09%
Oct 10, 2022
Downgrades: Neutral
Price Target: n/a
Current: $48.18
Upside: -
May 31, 2022
Upgrades: Buy
Price Target: n/a
Current: $67.74
Upside: -
Feb 25, 2020
Downgrades: Neutral
Price Target: n/a
Current: $108.95
Upside: -
Feb 3, 2020
Downgrades: Neutral
Price Target: n/a
Current: $6.83
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $56 → $54
Current: $1.25
Upside: +4,220.00%
Mar 8, 2018
Maintains: Market Perform
Price Target: $60 → $45
Current: $20.18
Upside: +122.99%
Feb 6, 2018
Maintains: Market Perform
Price Target: $36 → $38
Current: $68.95
Upside: -44.89%
Jan 31, 2018
Maintains: Market Perform
Price Target: $35 → $38
Current: $23.09
Upside: +64.57%